Investors
Sustaining long-term profitable growth
Sustaining long-term profitable growth
In September 2019, we set out the following strategic goals to guide our activities:
1. Sustain and extend our antibody and digital leadership (“Lead“)
2. Drive continued expansion into complementary market adjacencies (“Expand“)
3. Build organisational scalability and sustain value creation (“Scale“)
Underlying these goals are six growth strategies which form the foundation of our growth strategy and value creation plan for the medium-term. They are designed to help us grow together; not just as a Company, but as a global team, and to do so in an efficient and effective way.
Use the tabs below to explore our growth pillars and strategies:
1. Extend leadership in RUO antibodies
Our growth strategy starts with a commitment to extending our antibody leadership. Fundamental to our purpose, we are committed to help advance and accelerate our customers’ research and, in turn, support our market share gains. We seek to do this through the ongoing curation and expansion of our product portfolio, combined with the addition of data, knowledge and information that demonstrates the performance and increased utility of those products in a broader range of experiments and applications.
Our strategy is enhanced through our focus on in-house proprietary products, including one of the world’s largest portfolios of recombinant rabbit monoclonal antibodies. Through continuous innovation we are focused on ensuring that our portfolio is aligned with the targets, research areas and biological pathways in highest demand from our customers.
2. Remove innovation constraints and launch new lines
We are developing our innovation capabilities to meet a broader range of our customers’ needs. This is enabling us to grow within our addressable markets and at the same
time provides us with in-house tools to increase the rate at which we can expand our portfolio of in-house antibodies.
Specifically, we are focused on 1) antibody-derived products for high value, high growth markets, including immunoassays; 2) complementary product areas that simultaneously remove constraints to antibody innovation, including bioactive proteins and engineered cell lines; and 3) Providing antibodies and reagents to third-party instrumentation platforms and multiplex partners.
3. Be a leading discovery partner for biopharma organisations
Diagnostic and biopharmaceutical companies are increasingly seeking product development partners with unique antibody and assay development capabilities, such as ours, to complement their in-house programmes. Through our portfolio of high-performance in-house products, combined with a growing innovation, commercial and manufacturing capability, our goal is to be a leading discovery partner for these strategic customers. We believe this will lead to increased opportunities for the development of custom solutions, partnerships, and collaborations.
4. Be a leading digital company
Our digital platform and online presence remains an important differentiator in our markets. Our goal is to significantly enhance our digital channel by establishing a highly personalised digital relationship with our customers, which will be device agnostic, cloud based and driven by artificial intelligence. We believe this will help us to uniquely understand and anticipate researchers’ needs and to provide them with the right set of tools to advance their research. Through faster response to customers and greater personalisation of the user experience, we aim to provide our customers with more relevant content to support their work.
5. Remove scalability constraints and sustain value
Our objective is to strengthen our teams, systems and infrastructure while driving operational efficiency. We are focused on increasing our manufacturing capacity, increasing automation at process bottlenecks and optimising our global network and procurement functions. We are also transforming our systems and processes by implementing Oracle Cloud enterprise resource planning (“ERP”) and other software solutions to replace legacy information technology systems. We are also focused on expanding our operations in multiple high growth regions, including China.
6. Selectively pursue acquisitions
We have a strong track record of successfully identifying, completing and integrating strategic acquisitions and investments. Our strong brand, broad platform, global infrastructure and diversified customer base has allowed us to generate growth and operating leverage through acquisitions. We intend to continue to pursue opportunistic acquisitions in our existing and adjacent customer segments to accelerate our growth, expand geographic coverage and augment our capabilities and workflow solutions.
Sustain and expand antibody and digital leadership.
1. Extend leadership in RUO antibodies
Our growth strategy starts with a commitment to extending our antibody leadership. Fundamental to our purpose, we are committed to help advance and accelerate our customers’ research and, in turn, support our market share gains. We seek to do this through the ongoing curation and expansion of our product portfolio, combined with the addition of data, knowledge and information that demonstrates the performance and increased utility of those products in a broader range of experiments and applications.
Our strategy is enhanced through our focus on in-house proprietary products, including one of the world’s largest portfolios of recombinant rabbit monoclonal antibodies. Through continuous innovation we are focused on ensuring that our portfolio is aligned with the targets, research areas and biological pathways in highest demand from our customers.
4. Be a leading digital company
Our digital platform and online presence remains an important differentiator in our markets. Our goal is to significantly enhance our digital channel by establishing a highly personalised digital relationship with our customers, which will be device agnostic, cloud based and driven by artificial intelligence. We believe this will help us to uniquely understand and anticipate researchers’ needs and to provide them with the right set of tools to advance their research. Through faster response to customers and greater personalisation of the user experience, we aim to provide our customers with more relevant content to support their work.
6. Selectively pursue acquisitions
We have a strong track record of successfully identifying, completing and integrating strategic acquisitions and investments. Our strong brand, broad platform, global infrastructure and diversified customer base has allowed us to generate growth and operating leverage through acquisitions. We intend to continue to pursue opportunistic acquisitions in our existing and adjacent customer segments to accelerate our growth, expand geographic coverage and augment our capabilities and workflow solutions.
2. Remove innovation constraints and launch new lines
We are developing our innovation capabilities to meet a broader range of our customers’ needs. This is enabling us to grow within our addressable markets and at the same
time provides us with in-house tools to increase the rate at which we can expand our portfolio of in-house antibodies.
Specifically, we are focused on 1) antibody-derived products for high value, high growth markets, including immunoassays; 2) complementary product areas that simultaneously remove constraints to antibody innovation, including bioactive proteins and engineered cell lines; and 3) Providing antibodies and reagents to third-party instrumentation platforms and multiplex partners.
3. Be a leading discovery partner for biopharma organisations
Diagnostic and biopharmaceutical companies are increasingly seeking product development partners with unique antibody and assay development capabilities, such as ours, to complement their in-house programmes (see Our Markets). Through our portfolio of high-performance in-house products, combined with a growing innovation, commercial and manufacturing capability, our goal is to be a leading discovery partner for these strategic customers. We believe this will lead to increased opportunities for the development of custom solutions, partnerships, and collaborations.
6. Selectively pursue acquisitions
We have a strong track record of successfully identifying, completing and integrating strategic acquisitions and investments. Our strong brand, broad platform, global infrastructure and diversified customer base has allowed us to generate growth and operating leverage through acquisitions. We intend to continue to pursue opportunistic acquisitions in our existing and adjacent customer segments to accelerate our growth, expand geographic coverage and augment our capabilities and workflow solutions.
5. Remove scalability constraints and sustain value
Our objective is to strengthen our teams, systems and infrastructure while driving operational efficiency. We are focused on increasing our manufacturing capacity, increasing automation at process bottlenecks and optimising our global network and procurement functions. We are also transforming our systems and processes by implementing Oracle Cloud enterprise resource planning (“ERP”) and other software solutions to replace legacy information technology systems. We are also focused on expanding our operations in multiple high growth regions, including China.
6. Selectively pursue acquisitions
We have a strong track record of successfully identifying, completing and integrating strategic acquisitions and investments. Our strong brand, broad platform, global infrastructure and diversified customer base has allowed us to generate growth and operating leverage through acquisitions. We intend to continue to pursue opportunistic acquisitions in our existing and adjacent customer segments to accelerate our growth, expand geographic coverage and augment our capabilities and workflow solutions.
The more successful we can be as a business, the greater the difference we can make in the world. That extends to doing business the right way. In 2020 we undertook our most comprehensive effort yet to understand and measure our impact in the form of a Sustainability Review that involved engaging with a broad range of stakeholders. You can read more about this at the link below:
Read about the financial and strategic progress made in 2020.
Read about the financial and strategic progress made in 2020.
Explore our business model and how we sustain value creation for our stakeholders
Read about our markets and their long-term growth drivers
View our latest financial results
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
© Abcam plc. all rights reserved.
Abcam plc is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds. Static content was last updated on 09 Nov 2020.
Website by FisherPaul
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy policy